| Literature DB >> 25040161 |
Abstract
Host immunity is a major driver of pathogen evolution and thus a major determinant of pathogen diversity. Explanations for pathogen diversity traditionally assume simple interactions between pathogens and the immune system, a view encapsulated by the susceptible-infected-recovered (SIR) model. However, there is growing evidence that the complexity of many host-pathogen interactions is dynamically important. This revised perspective requires broadening the definition of a pathogen's immunological phenotype, or what can be thought of as its immunological niche. After reviewing evidence that interactions between pathogens and host immunity drive much of pathogen evolution, I introduce the concept of a pathogen's immunological phenotype. Models that depart from the SIR paradigm demonstrate the utility of this perspective and show that it is particularly useful in understanding vaccine-induced evolution. This paper highlights questions in immunology, evolution, and ecology that must be answered to advance theories of pathogen diversity.Entities:
Keywords: bacteria; evolutionary epidemiology; host-pathogen interactions; infectious diseases; influenza; niche theory; phylodynamics; viruses
Mesh:
Substances:
Year: 2014 PMID: 25040161 PMCID: PMC4141700 DOI: 10.1111/nyas.12493
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN: 0077-8923 Impact factor: 5.691
Several pathogens infecting humans, for which positive selection on immune phenotype has been demonstrated
| Pathogen | Variable target | Induced response | Sample references |
|---|---|---|---|
| Viruses | |||
| Influenza | Surface proteins hemagglutinin and neuraminidase | Antibodies, CD8+ T cells, CD4+ T cells | Refs. |
| Hepatitis C | NS3 and NS5A regions | CD8+ T cells | Ref. |
| Norovirus | Surface proteins | Antibodies | Ref. |
| HIV | Gag protein gp120 | CD8+ T cells, antibodies | Refs. |
| Rhinovirus | Surface proteins | Antibodies | Ref. |
| Rotavirus | Surface proteins VP3 and VP7 | Antibodies | Ref. |
| Bacteria | |||
| | Polysaccharide capsule, subcapsular protein antigens | Antibodies, CD4+ T cells | Refs. |
| | PiLE pilus protein | Antibodies | Refs. |
| Protozoa | |||
| | PfEMP1 | Antibodies | Ref. |
| | Surface glycoprotein VSG | Antibodies | Ref. |
Figure 1Four views of a pathogen's immune phenotype. (A) The approximate strength, duration, and breadth of influenza virus's interactions with three major components of host immunity. The strength of the response, measured by its impact on fitness, is illustrated by the darkness of the shading. (B) The antigenic evolution of a simulated influenza virus population, collapsed into two arbitrary antigenic dimensions (principal components), from Ref. 100. (C) Network of shared epitopes of a population of four pathogen strains, each with two potential alleles at each of two loci. No population substructure is apparent. (D) Networks of realized relationships for two individual hosts. One host has developed immunity or is restricted (e.g., by MHC) to developing immunity to the first locus, and the other host to the second locus. Each host views a structured population of two phenotypes, but these population structures vary between hosts.
Figure 2The potential effects of a multivalent vaccine on the evolution of pneumococcal serotypes depend on two mechanisms of immune interaction and differences between natural and vaccine-induced immunity. Natural immunity to pneumococcus includes serotype-specific (antibody-mediated) and nonspecific (CD4+ T cell–mediated) components. Vaccine-induced immunity confers antibody protection only. Acquired serotype-specific immunity from natural carriage is assumed to reduce susceptibility to future colonizations with that serotype by a fraction σc (with σc = 1, implying complete protection; estimates are σc ∼ 0.3–0.6). Figures show the prevalence of each serotype in pre- and postvaccine eras. Simulations assume 100% of the population is vaccinated beginning in the year 400.110 (A) Vaccine-induced serotype-specific immunity σv is slightly weaker than natural serotype-specific immunity σc (σc > σv). Some of the targeted serotypes (red) return a few decades following vaccination. (B) Vaccine-induced serotype-specific immunity is stronger than natural serotype-specific immunity (σc < σv). A vaccine with high valency can allow targeted serotypes to return due to the gradual loss of nonspecific immunity.